Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 159,611 shares at $126.51 ($19.9M) on 2023-06-07, disclosed to the SEC on 2023-06-09.
Scheduled sale ($19.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $125.73 | 35,872 | $4.5M | 22.6% |
| 2 | $125.73 | 35,872 | $4.5M | 22.6% |
| 3 | $126.51 | 4,128 | $522K | 2.6% |
| 4 | $126.51 | 4,128 | $522K | 2.6% |
| 5 | $123.58 | 22,215 | $2.7M | 13.8% |
| 6 | $123.58 | 22,215 |
| $2.7M |
| 13.8% |
| 7 | $124.53 | 17,396 | $2.2M | 10.9% |
| 8 | $124.53 | 17,396 | $2.2M | 10.9% |
| 9 | $125.22 | 389 | $49K | 0.2% |
| Total | $124.91 avg | 159,611 | $19.9M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |